Impact of Glutathione (GSH) Supplementation in Mild Cognitive Impairment (MCI) Patients: A Randomized Control Trial

ational Brain Research Centre0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

研究概览

暂无简介。

•i. Patients diagnosed with amnestic MCI.
•ii. Acceptance of taking the supplements as directed and compliant to follow-up data assessment.
•iii. Screening Tests:
•a. Standardized mini-mental state examination (SMMSE) score should be obtained between 20 to 25.
•b. Clinical dementia rating (CDR) scale should be equal to 0.5.
•c. MRI safety screening test to be performed before undergoing for MRI procedure.
•iv. Participants should be able to understand as well as speak Hindi or English.

•i. Participants with any metallic implants or claustrophobic or having any contraindication to MRI and MRS.
•ii. Patients suffering from any severe acute or chronic comorbid condition (COPD, chronic cardiovascular diseases, chronic liver disease, chronic kidney disease or any immunological disorder, etc.).
•iii. Patients with any other neurological or neuropsychological, or psychiatric illness (other than primary indication).
•iv. Participants with known hypersensitivity to any component of the GSH supplement.
•v. Participants undertaking any other antioxidant within 90 days prior to the enrolment.
•vi. Participants with whom compliance with follow-up is unlikely.
•vii. Participants who are not willing to give consent will also be excluded.

发起方

ational Brain Research Centre